DERICIP RETARD 300 (Etofylline (231mg) + Theophylline (69mg))

Dericip Retard 300 is a medication that features a combination of Etofylline, at a concentration of 231 mg, and Theophylline, at 69 mg, both in a formulation that allows for sustained release. This product is intended to assist in managing respiratory conditions, including asthma and chronic obstructive pulmonary disease (COPD). The active component, Etofylline, serves as a bronchodilator, which means it works by relaxing the muscles surrounding the airways, thus facilitating improved airflow and breathing. The addition of Theophylline contributes to enhanced lung performance through the dilation of bronchial passages. This synergistic effect aims to reduce common symptoms associated with respiratory disorders, such as wheezing, difficulties in breathing, and feelings of tightness in the chest. By providing prolonged relief, Dericip Retard 300 is designed to offer patients better control over their respiratory issues, helping to improve their overall quality of life. It is essential, however, for patients to consult their healthcare provider for proper assessment and monitoring while using this medication, especially in the context of any existing health conditions or other treatments being administered. Use this medicine only under medical supervision. Follow the dose and schedule exactly as advised. Do not stop abruptly without guidance. Keep a record of any unusual symptoms and share them with your clinician. Combine therapy with appropriate lifestyle measures and routine monitoring as recommended.